Prihlásiť sa Zaregistrujte sa zadarmo

Trhová kapitalizácia spoločnosti Kazia Therapeutics

Aká je hodnota metriky Trhová kapitalizácia spoločnosti Kazia Therapeutics?

Hodnota metriky Trhová kapitalizácia spoločnosti Kazia Therapeutics Limited je $9.01M

Aká je definícia metriky Trhová kapitalizácia?



Trhová kapitalizácia (Market cap) je trhová hodnota vydaných akcií obchodovanej spoločnosti a je rovná cene akcie v danom čase vynásobenej počtom kusov vydaných akcií.

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Trhová kapitalizácia spoločností v sektore Health Care sektor na ASX v porovnaní so spoločnosťou Kazia Therapeutics

Čomu sa venuje spoločnosť Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Firmy s metrikou trhová kapitalizácia podobnou spoločnosti Kazia Therapeutics